NCT02467868已完成3 期
Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Mylan Inc.
- 入组人数
- 193
- 试验地点
- 40
- 主要终点
- Mean Duration of Severe Neutropenia (DSN), defined as consecutive days with absolute neutrophil count (ANC) < 0.5 × 109/L
研究概览
简要总结
This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.
详细描述
After successful screening, eligible patients will be randomly allocated to one of the two study arms, either receiving MYL-1401H or Neulasta.
Randomization is 2:1 to MYL-1401H or Neulasta, respectively.
Subjects will receive first of six cycles of background therapy (Docetaxel, Doxorubicin, Cyclophosphamide [TAC]) on day 1. Treatment with study drug (either MYL-1401H or Neulasta) is scheduled on Day 2 of each cycle, at least 24 hours after chemotherapy administration.
Duration of each cycle is 3 weeks.
Follow-up visit is scheduled 24 weeks after the first administration of study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated written informed consent.
- •Patients ≥18 years.
- •Women of child-bearing potential must agree to use effective methods of birth control during the treatment period from the first dose of study drug until 6 months following the last dose of study drug.
- •Newly diagnosed, pathologically confirmed breast cancer.
- •Stage II or III breast cancer with adequate staging workup and adequate surgery if receiving adjuvant therapy.
- •Patients planned/eligible to receive neoadjuvant or adjuvant treatment with (Docetaxel, Doxorubicin, Cyclophosphamide [TAC]) for their breast cancer.
- •Cancer Chemotherapy and Radiotherapy naïve.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- •Absolute neutrophil count ≥ 1.5 × 109/L ; Platelet count ≥ 100 × 109/L ;
- •Hemoglobin > 10 g/dL without blood transfusions or cytokine support during the two weeks previous to the hemoglobin level.
- •Adequate cardiac function (including left ventricular ejection fraction ≥ 50% as assessed by echocardiography) within 4 weeks prior to start of chemotherapy.
- •Adequate renal function, i.e., creatinine < 1.5 × upper limit of normal (ULN).
- •Other protocol specific inclusion/exclusion criteria may apply
排除标准
- •Participation in a clinical trial in which they received an investigational drug within 28 days before randomization.
- •Previous exposure to filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, or other filgrastim forms on the market or in clinical development.
- •Received blood transfusions or erythroid growth factors within 2 weeks prior to first dose of chemotherapy.
- •Known hypersensitivity to any drugs or excipients that patients will be receiving during the study.
- •Known hypersensitivity to E. coli-derived products.
- •Known fructose intolerance (related with sorbitol excipient).
- •Underlying neuropathy of grade 2 or higher.
- •Active infectious disease or any other medical condition which might put the patient at significant risk to tolerate 6 courses of TAC chemotherapy (e.g., recent myocardial infarction).
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × Upper limit of normal (ULN), ALT and/or AST > 1.5 × ULN with alkaline phosphatase (ALP) > 2.5 × ULN; any bilirubin > ULN.
- •Treatment with systemically active antibiotics within 5 days before first dose of chemotherapy.
- •Patients under treatment with lithium.
- •Chronic use of oral corticosteroids.
- •Splenomegaly of unknown origin by physical examination and/or computerized tomography scan or ultrasound and any condition which can cause splenomegaly, e.g., thalassemia, glandular fever, hemolytic anemias, and malaria.
- •Myeloproliferative or myelodysplastic disorders, sickle cell disorders, and any illness or condition that in the opinion of the investigator may affect the safety of the patient or the evaluation of any study endpoint.
- •Increase potential risk of Adult Respiratory Distress Syndrome.
- •Pregnant or nursing women.
- •Patients known to be seropositive for human immunodeficiency virus (HIV), or who have had an acquired immunodeficiency syndrome (AIDS) defining illness or a known immunodeficiency disorder.
- •A known active abuse of drugs or alcohol should preclude patient participation and evaluation in the study.
- •Any known psychiatric conditions.
- •Any disease or physical condition that may not allow for the adequate performance of study assessments, such as lack of access to patient's domiciliary, and distance of patient's domiciliary from clinic site.
结局指标
主要结局
Mean Duration of Severe Neutropenia (DSN), defined as consecutive days with absolute neutrophil count (ANC) < 0.5 × 109/L
时间窗: Cycle 1 of chemotherapy (approx 21 days)
次要结局
- The rate of febrile neutropenia (FN)(Week 24 (End of the study))
研究者
研究点 (40)
Loading locations...
相似试验
进行中（未招募）
不适用
Treatment of Knee Osteoarthritis With PAAG-OAOsteoarthritis, KneeNCT04045431Contura238
终止
2 期
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.Non Alcoholic Steatohepatitis (NASH)NCT04065841Novartis Pharmaceuticals234
已完成
2 期
Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic TorticollisCervical DystoniaSpasmodic TorticollisNCT00165776Eisai Co., Ltd.133
已完成
3 期
A Phase 3 Study in Participants With Moderate to Severe PsoriasisPsoriasisNCT01474512Eli Lilly and Company1,296
已完成
3 期
A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive BladderOveractive BladderNCT00685113Duramed Research1,104